Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
REGENERON PHARMACEUTICALS, INC.
Next earnings ≈ Jul 29, 2026 · est. from filing cadence
Last earnings -6.2% on 2026-04-29
Strong net margin (31.4%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
REGENERON PHARMACEUTICALS, INC. shows $14.3B in FY2025 revenue (+1.0% YoY), a 31.4% net margin, and 14.4% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0000872589, latest 10-Q filed 2026-04-29) · EODHD · rules-based read · as of 6/17/2026, 7:45:49 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Gross profit | — | — | — | — | — |
| Operating income | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B |
| Net income | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| Diluted EPS | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Net margin | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
58 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Last 90 days: 0 open-market buys · 21 sales
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 5.00 @ $701.76 | $3.51K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 15.00 @ $702.46 | $10.5K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 24.00 @ $703.46 | $16.9K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 15.00 @ $704.28 | $10.6K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 14.00 @ $705.56 | $9.88K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 7.00 @ $706.74 | $4.95K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 4.00 @ $707.40 | $2.83K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 6.00 @ $709.45 | $4.26K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 2.00 @ $710.87 | $1.42K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 5.00 @ $711.49 | $3.56K |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 1.00 @ $712.09 | $712.09 |
| 2026-05-01 | RYAN ARTHUR F Director | Sell | 2.00 @ $714.13 | $1.43K |